Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NUVL

Nuvalent Inc

Apr 10 • 04:00PM ET

102.74

-1.85 -1.77 %

Healthcare • Biotechnology • USA • NASD

Peers: ARQT ABUS TIL ALLO BEAM IMTX KRYS RGNX DTIL

| Held by: VTI VB IWM XBI VBR VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.85	Insider Own	33.99%	Shs Outstand	72.80M	Perf Week	-2.55%
Market Cap	8.08B	Forward P/E	-	EPS next Y	-4.28	Insider Trans	-4.50%	Shs Float	51.89M	Perf Month	2.69%
Enterprise Value	6.71B	PEG	-	EPS next Q	-1.34	Inst Own	80.42%	Short Float	9.59%	Perf Quarter	0.07%
Income	-425.38M	P/S	-	EPS this Y	4.95%	Inst Trans	11.26%	Short Ratio	9.02	Perf Half Y	21.07%
Sales	0.00M	P/B	6.44	EPS next Y	23.07%	ROA	-33.30%	Short Interest	4.98M	Perf YTD	2.14%
Book/sh	15.96	P/C	5.89	EPS next 5Y	44.35%	ROE	-36.70%	52W High	113.01 -9.09%	Perf Year	65.74%
Cash/sh	17.45	P/FCF	-	EPS past 3/5Y	-52.56% -80.97%	ROIC	-34.08%	52W Low	58.05 76.99%	Perf 3Y	299.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.51% 3.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-49.51%	Oper. Margin	-	ATR (14)	3.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.41	Recom	1.16
Dividend Gr. 3/5Y	- -	Current Ratio	15.27	EPS Q/Q	-50.85%	SMA20	2.76%	Beta	1.28	Target Price	142.39
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.31%	Rel Volume	0.75	Prev Close	104.59
Employees	228	LT Debt/Eq	0.00	Earnings	Feb 26 BMO	SMA200	10.29%	Avg Volume	551.49K	Price	102.74
IPO	Jul 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.08% -	Trades		Volume	412,854	Change	-1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-26	Initiated	Wells Fargo	Overweight	$116
Nov-24-25	Initiated	Truist	Buy
Nov-12-25	Initiated	Canaccord Genuity	Buy	$126
Oct-16-25	Resumed	Stifel	Buy	$115
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight	$135
Sep-04-25	Resumed	Guggenheim	Buy	$122
Sep-03-25	Initiated	Raymond James	Outperform	$105
Aug-19-25	Initiated	Piper Sandler	Overweight	$112
Mar-14-25	Upgrade	UBS	Neutral → Buy	$100
Dec-30-24	Initiated	H.C. Wainwright	Buy	$110
Oct-24-24	Initiated	UBS	Neutral	$100
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39

Show Previous Ratings

Apr-07-26 06:30AM	Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC (PR Newswire)
Feb-27-26 09:55AM	Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? (Zacks)
Feb-26-26 06:30AM	Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-14-26 12:03PM	Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans (MarketBeat)
Feb-05-26 06:30AM	Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (PR Newswire)
10:42AM	Loading…
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
Jan-12-26 06:30AM	Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones (PR Newswire) -5.61%
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-22-25 06:30AM	Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-10-25 04:01PM	Nuvalent Appoints Ron Squarer to Board of Directors (PR Newswire)
Dec-09-25 12:20AM	Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects (Insider Monkey)
Nov-26-25 06:30AM	Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-24-25 04:01PM	Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders (PR Newswire)
Nov-19-25 04:19PM	Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC (PR Newswire)
Nov-18-25 11:50PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
06:24AM	Loading…
06:24AM	Nuvalent aiming for approval on pivotal trial data for NSCLC candidate (Clinical Trials Arena)
Nov-17-25 04:40PM	Nuvalent Tops A Profit-Taking Zone On Its 'Unprecedented' Test Results In Lung Cancer (Investor's Business Daily) +11.92%
04:01PM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
06:32AM	Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer (Investor's Business Daily)
06:30AM	Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC (PR Newswire)
Nov-14-25 04:01PM	Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib (PR Newswire)
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 05:12PM	Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer (PR Newswire)
Oct-30-25 06:30AM	Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-18-25 06:00AM	Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 (PR Newswire)
Oct-13-25 12:53PM	Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-24-25 06:30AM	Nuvalent to Participate in the UBS 2025 Virtual Oncology Day (PR Newswire)
Sep-07-25 04:45AM	Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 (PR Newswire)
Sep-02-25 01:34AM	Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts (Insider Monkey)
Aug-28-25 06:30AM	Nuvalent to Participate in the Cantor Global Healthcare Conference 2025 (PR Newswire)
01:06PM	Loading…
Aug-13-25 01:06PM	Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium (PR Newswire)
Aug-07-25 06:30AM	Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) -6.56%
Jul-21-25 06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC (PR Newswire)
06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naive ALK-positive NSCLC (PR Newswire)
Jul-06-25 04:00AM	Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer (Insider Monkey)
Jun-25-25 10:20AM	Nuvalent price target raised to $140 from $125 at Leerink (TipRanks)
10:15AM	Nuvalent price target raised to $130 from $110 at H.C. Wainwright (TipRanks)
Jun-24-25 06:30AM	Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC (PR Newswire)
06:30AM	Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug (BioPharma Dive)
Jun-23-25 04:30PM	Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib (PR Newswire)
Jun-18-25 04:30PM	Nuvalent Appoints Christy Oliger to Board of Directors (PR Newswire)
May-08-25 07:31AM	Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results (PR Newswire) +7.31%
Apr-29-25 01:09PM	Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor (PR Newswire)
Apr-23-25 08:48PM	Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
12:47PM	Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
10:28AM	Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-08-25 04:00PM	Nuvalent: Cannot Make Sense Of The Valuation (Seeking Alpha) -8.29% +9.07%
Apr-01-25 08:25AM	Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? (Insider Monkey)
06:30AM	Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (PR Newswire)
Mar-25-25 05:24PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Feb-28-25 06:30AM	Nuvalent to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-27-25 06:30AM	Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 01:47PM	Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently (Insider Monkey)
Jan-20-25 03:07PM	Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-13-25 06:30AM	Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones (PR Newswire) -6.20%
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly)
Dec-19-24 06:30AM	Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 06:30AM	Nuvalent Appoints Grant Bogle to Board of Directors (PR Newswire)
Nov-26-24 06:52AM	Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-12-24 06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results (PR Newswire)
Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Porter James Richard	President and CEO	Apr 06 '26	Option Exercise	23.77	30,000	713,171	354,879	Apr 08 04:30 PM
Porter James Richard	President and CEO	Apr 06 '26	Sale	103.77	30,000	3,113,231	324,879	Apr 08 04:30 PM
Balcom Alexandra	Chief Financial Officer	Apr 01 '26	Option Exercise	1.08	11,430	12,344	96,963	Apr 03 04:30 PM
Balcom Alexandra	Chief Financial Officer	Apr 01 '26	Sale	105.21	11,430	1,202,527	85,533	Apr 03 04:30 PM
Noci Darlene	Chief Development Officer	Mar 30 '26	Option Exercise	27.85	5,500	153,175	63,617	Apr 01 04:30 PM
Noci Darlene	Chief Development Officer	Mar 30 '26	Sale	97.81	5,500	537,943	58,117	Apr 01 04:30 PM
Darlene Noci	Officer	Mar 30 '26	Proposed Sale	96.66	22,000	2,126,520		Mar 30 05:57 PM
Miller Deborah Ann	Chief Legal Officer	Mar 26 '26	Option Exercise	6.89	5,500	37,895	65,134	Mar 30 05:31 PM
Miller Deborah Ann	Chief Legal Officer	Mar 26 '26	Sale	98.73	5,500	542,991	59,634	Mar 30 05:31 PM
Balcom Alexandra	Chief Financial Officer	Mar 24 '26	Option Exercise	1.08	11,430	12,344	110,663	Mar 26 04:30 PM
Balcom Alexandra	Chief Financial Officer	Mar 25 '26	Sale	100.16	13,700	1,372,192	85,533	Mar 26 04:30 PM
Balcom Alexandra	Chief Financial Officer	Mar 24 '26	Sale	95.75	11,430	1,094,418	99,233	Mar 26 04:30 PM
Alexandra Balcom	Officer	Mar 24 '26	Proposed Sale	96.43	59,420	5,729,870		Mar 24 06:32 PM
Pelish Henry E.	Chief Scientific Officer	Mar 12 '26	Option Exercise	31.52	17,320	545,872	100,708	Mar 16 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Mar 12 '26	Sale	97.92	30,000	2,937,685	70,708	Mar 16 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Mar 13 '26	Sale	98.98	5,104	505,171	65,604	Mar 16 04:31 PM
HENRY E PELISH	Officer	Mar 12 '26	Proposed Sale	100.05	38,197	3,821,610		Mar 12 04:38 PM
Porter James Richard	President and CEO	Mar 06 '26	Option Exercise	27.85	30,000	835,500	354,879	Mar 10 04:30 PM
Porter James Richard	President and CEO	Mar 06 '26	Sale	98.99	30,000	2,969,550	324,879	Mar 10 04:30 PM
James Richard Porter	Officer	Mar 06 '26	Proposed Sale	97.96	90,000	8,816,400		Mar 06 04:01 PM
Noci Darlene	Chief Development Officer	Feb 26 '26	Option Exercise	27.85	5,500	153,175	63,617	Mar 02 04:34 PM
Noci Darlene	Chief Development Officer	Feb 26 '26	Sale	103.03	5,500	566,682	58,117	Mar 02 04:34 PM
Miller Deborah Ann	Chief Legal Officer	Feb 26 '26	Option Exercise	6.89	5,500	37,895	65,134	Mar 02 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Feb 26 '26	Sale	103.05	5,500	566,788	59,634	Mar 02 04:32 PM
Matthew Shair	Director	Feb 17 '26	Proposed Sale	100.68	1,650	166,125		Feb 17 04:58 PM
Matthew Shair	Director	Feb 17 '26	Proposed Sale	100.68	5,850	588,990		Feb 17 04:45 PM
Noci Darlene	Chief Development Officer	Jan 29 '26	Option Exercise	27.85	5,500	153,175	63,617	Feb 02 04:30 PM
Noci Darlene	Chief Development Officer	Jan 29 '26	Sale	102.08	5,500	561,422	58,117	Feb 02 04:30 PM
Miller Deborah Ann	Chief Legal Officer	Jan 22 '26	Option Exercise	27.85	14,300	398,255	73,934	Jan 23 04:31 PM
Miller Deborah Ann	Chief Legal Officer	Jan 21 '26	Option Exercise	27.85	700	19,495	60,334	Jan 23 04:31 PM
Miller Deborah Ann	Chief Legal Officer	Jan 22 '26	Sale	110.16	14,300	1,575,288	59,634	Jan 23 04:31 PM
Miller Deborah Ann	Chief Legal Officer	Jan 21 '26	Sale	109.84	700	76,888	59,634	Jan 23 04:31 PM
DEBORAH MILLER	Officer	Jan 22 '26	Proposed Sale	109.04	21,000	2,289,840		Jan 22 04:33 PM
Pelish Henry E.	Chief Scientific Officer	Jan 06 '26	Sale	97.17	2,664	258,848	65,888	Jan 07 05:27 PM
Pelish Henry E.	Chief Scientific Officer	Jan 05 '26	Sale	97.32	2,496	242,905	68,552	Jan 07 05:27 PM
Noci Darlene	Chief Development Officer	Jan 05 '26	Sale	97.32	4,236	412,239	43,798	Jan 07 05:26 PM
Noci Darlene	Chief Development Officer	Jan 06 '26	Sale	97.16	3,181	309,081	40,617	Jan 07 05:26 PM
Miller Deborah Ann	Chief Legal Officer	Jan 05 '26	Sale	97.32	4,363	424,598	44,723	Jan 07 05:26 PM
Miller Deborah Ann	Chief Legal Officer	Jan 06 '26	Sale	97.16	2,589	251,560	42,134	Jan 07 05:26 PM
Turner Christopher Durant	Chief Medical Officer	Jan 05 '26	Sale	97.32	4,236	412,239	58,311	Jan 07 05:26 PM
Turner Christopher Durant	Chief Medical Officer	Jan 06 '26	Sale	97.16	3,181	309,081	55,130	Jan 07 05:26 PM
Balcom Alexandra	Chief Financial Officer	Jan 05 '26	Sale	97.32	4,236	412,239	84,914	Jan 07 05:25 PM
Balcom Alexandra	Chief Financial Officer	Jan 06 '26	Sale	97.16	3,181	309,081	81,733	Jan 07 05:25 PM
Porter James Richard	President and CEO	Jan 05 '26	Sale	97.32	17,890	1,741,016	288,172	Jan 07 05:25 PM
Porter James Richard	President and CEO	Jan 06 '26	Sale	97.16	9,543	927,244	278,629	Jan 07 05:25 PM
Henry E. Pelish	Officer	Jan 05 '26	Proposed Sale	97.32	2,496	242,901		Jan 05 08:58 PM
Darlene Noci	Officer	Jan 05 '26	Proposed Sale	97.32	4,236	412,232		Jan 05 08:58 PM
Deborah Ann Miller	Officer	Jan 05 '26	Proposed Sale	97.32	4,363	424,591		Jan 05 08:57 PM
Christopher Durant Turner	Officer	Jan 05 '26	Proposed Sale	97.32	4,236	412,232		Jan 05 08:55 PM
Alexandra Balcom	Officer	Jan 05 '26	Proposed Sale	97.32	4,236	412,232		Jan 05 08:54 PM
James Richard Porter	Officer	Jan 05 '26	Proposed Sale	97.32	17,890	1,740,989		Jan 05 08:53 PM
Noci Darlene	Chief Development Officer	Dec 30 '25	Option Exercise	27.85	4,000	111,400	52,034	Jan 02 04:20 PM
Noci Darlene	Chief Development Officer	Dec 30 '25	Sale	100.04	4,000	400,179	48,034	Jan 02 04:20 PM
Darlene Noci	Officer	Dec 30 '25	Proposed Sale	101.60	15,000	1,524,000		Dec 30 04:03 PM
Pelish Henry E.	Chief Scientific Officer	Dec 22 '25	Option Exercise	1.08	5,085	5,492	71,048	Dec 23 04:31 PM
Balcom Alexandra	Chief Financial Officer	Dec 22 '25	Option Exercise	1.08	34,500	37,260	89,150	Dec 23 04:30 PM
Porter James Richard	President and CEO	Dec 19 '25	Option Exercise	0.65	57,000	37,050	306,062	Dec 23 04:30 PM
Balcom Alexandra	Chief Financial Officer	Dec 08 '25	Sale	110.32	7,084	781,537	54,650	Dec 10 04:30 PM
Alexandra Balcom	Officer	Dec 08 '25	Proposed Sale	109.60	7,084	776,406		Dec 08 08:36 PM
Noci Darlene	Chief Development Officer	Nov 28 '25	Option Exercise	27.85	4,000	111,400	52,034	Dec 02 04:30 PM
Noci Darlene	Chief Development Officer	Nov 28 '25	Sale	108.58	4,000	434,319	48,034	Dec 02 04:30 PM
Shair Matthew	Director	Nov 24 '25	Sale	109.37	5,850	639,814	1,377,194	Nov 26 04:30 PM
Shair Matthew	Director	Nov 24 '25	Sale	109.37	1,650	180,460	201,672	Nov 26 04:30 PM
Flynn James E	Director by Deputization	Nov 24 '25	Sale	95.44	742,574	70,874,975	8,299,225	Nov 24 08:00 PM
Balcom Alexandra	Chief Financial Officer	Nov 17 '25	Option Exercise	49.85	20,000	996,962	81,734	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 18 '25	Option Exercise	72.35	729	52,743	62,463	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 17 '25	Sale	99.45	20,000	1,989,025	61,734	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 18 '25	Sale	104.26	729	76,005	61,734	Nov 19 05:14 PM
Miller Deborah Ann	Chief Legal Officer	Nov 17 '25	Option Exercise	6.89	24,200	166,738	73,286	Nov 19 05:13 PM
Miller Deborah Ann	Chief Legal Officer	Nov 17 '25	Sale	105.50	24,200	2,552,999	49,086	Nov 19 05:13 PM
DEBORAH MILLER	Officer	Nov 17 '25	Proposed Sale	96.50	17,200	1,659,800		Nov 17 04:37 PM
Alexandra Balcom	Officer	Nov 17 '25	Proposed Sale	93.72	13,854	1,298,397		Nov 17 04:09 PM
Noci Darlene	Chief Development Officer	Oct 30 '25	Option Exercise	27.85	4,000	111,400	52,034	Oct 31 04:31 PM
Noci Darlene	Chief Development Officer	Oct 30 '25	Sale	102.92	4,000	411,661	48,034	Oct 31 04:31 PM
Miller Deborah Ann	Chief Legal Officer	Oct 30 '25	Option Exercise	6.89	21,800	150,202	70,886	Oct 31 04:30 PM
Miller Deborah Ann	Chief Legal Officer	Oct 30 '25	Sale	103.16	21,800	2,248,943	49,086	Oct 31 04:30 PM
DEBORAH MILLER	Officer	Oct 30 '25	Proposed Sale	102.97	22,800	2,347,716		Oct 30 04:16 PM
Shair Matthew	Director	Oct 28 '25	Sale	100.27	32,455	3,254,263	1,383,044	Oct 29 04:31 PM
Shair Matthew	Director	Oct 27 '25	Sale	100.23	14,345	1,437,799	1,415,499	Oct 29 04:31 PM
Shair Matthew	Director	Oct 28 '25	Sale	100.27	9,154	917,872	203,322	Oct 29 04:31 PM
Shair Matthew	Director	Oct 27 '25	Sale	100.23	4,046	405,531	212,476	Oct 29 04:31 PM
Matthew Shair	Director	Oct 27 '25	Proposed Sale	100.00	64,350	6,435,000		Oct 27 04:09 PM
Matthew Shair	Director	Oct 27 '25	Proposed Sale	100.00	18,150	1,815,000		Oct 27 04:06 PM
Miller Deborah Ann	Chief Legal Officer	Oct 20 '25	Option Exercise	6.89	5,000	34,450	54,086	Oct 22 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 20 '25	Sale	94.91	5,000	474,550	49,086	Oct 22 04:32 PM
Porter James Richard	President and CEO	Oct 16 '25	Option Exercise	18.93	27,000	511,110	276,062	Oct 17 04:32 PM
Porter James Richard	President and CEO	Oct 16 '25	Sale	90.63	27,000	2,447,021	249,062	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Option Exercise	6.89	15,624	107,649	64,710	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Option Exercise	6.89	12,376	85,271	61,462	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Sale	89.98	15,624	1,405,848	49,086	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Sale	91.66	12,376	1,134,442	49,086	Oct 17 04:32 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Option Exercise	35.08	14,205	498,260	80,168	Oct 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Sale	90.04	14,205	1,279,018	65,963	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Option Exercise	18.93	1,683	31,859	63,417	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Sale	85.57	1,683	144,014	61,734	Oct 17 04:31 PM
James Richard Porter	Officer	Oct 16 '25	Proposed Sale	90.01	27,000	2,430,270		Oct 16 04:02 PM
DEBORAH MILLER	Officer	Oct 15 '25	Proposed Sale	84.66	54,000	4,571,640		Oct 15 04:37 PM
Balcom Alexandra	Chief Financial Officer	Oct 14 '25	Option Exercise	18.93	20,000	378,600	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Option Exercise	14.79	20,000	295,825	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Sale	88.51	20,000	1,770,288	61,734	Oct 15 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUVL

Nuvalent Inc

Upgrade your Finviz experience